Pharma BD Deal Intelligence
Boca was projected to deliver ~$50M EBITDA in FY2013 and be immediately accretive to Endo's adjusted diluted EPS — framed as the first of several roll-up…
Endo 'has reached an agreement to purchase privately-held Boca Pharmacal for $225m to improve its generics business, as a result of two of its biggest drugs…
FTC conditioned the deal on divestiture of four generic pediatric multivitamin-with-fluoride drop products (PolyViFlor, TriViFlor variants) plus three pipeline…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Endo's Qualitest subsidiary closed its $225M cash acquisition of privately held specialty generics company Boca Pharmacal, expanding its niche generics franchise in controlled substances and semi-solids. FTC required divestiture of certain generic multivitamin fluoride drops to clear the deal.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Endo Health Solutions Inc. / Boca Pharmacal, LLC (this deal) | 2014 | $225M | 21 |
| Endo Health Solutions Inc. / Paladin Labs Inc. | 2013 | $1.6B | 28 |
| Endo Health Solutions Inc. / Boca Pharmacal, LLC | 2013 | $225M | 19 |
| Endo Health Solutions Inc. / NuPathe Inc. | 2013 | $271M | — |
| Watson Pharmaceuticals (Actavis Inc.) / Actavis plc | 2012 | $5.9B | 97 |
| Kohlberg Kravis Roberts & Co. / PRA International (Genstar Capital) | 2013 | $1.3B | 91 |
| Stryker Corporation / MAKO Surgical Corp. | 2013 | $1.6B | 91 |
← Browse all deals · How we score deals
More: 2014 deals · Endo Health Solutions Inc. deals · Other deals